ADNI3 Study sites have been closely monitoring the COVID-19 situation. The safety of participants and site personnel are of the utmost importance to us. Our sites will follow state and local guidance on how and when to conduct in-person research activities for the ADNI3 Study. We ask that our current and prospective study participants stay in contact with their local site personnel to get the latest guidance and information. We will update our website with additional information as we continue to navigate this pandemic and learn more about best practices for safely conducting clinical research.
As ADNI investigators, we are acutely aware of the need for diversity, equity, and inclusion in our study. We recognize that the current ADNI cohort needs improved representation of Black, Latinx, and other under-represented minorities to reflect the diversity of older people in the US. This will be one of the core goals of ADNI in the coming years.
This issue has taken on greater urgency in the current social climate. The ADNI sites are preparing to re-open as local restrictions are being eased following the COVID shutdown. We are planning to use ADNI’s financial resources to accelerate enrollment of under-represented minorities during the final two years of ADNI 3.
We will work together, in scientific collaboration, to do a better job for all of the people in our community.
Sincerely,
The ADNI Leadership
Alzheimer's is an irreversible, progressive brain disease that gradually destroys memory, thinking skills, and eventually the ability to perform basic tasks. Currently, there is no way to prevent, cure, or slow the progression of Alzheimer's disease.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a historic study of brain aging looking to help increase the pace of discovery in the race to prevent, treat and one day cure Alzheimer’s disease. For more than a decade, ADNI researchers have been working to better understand the disease.
Now, in this next step, this initiative is studying how quickly brain cognition and function changes. ADNI3 is defining how best to measure these changes and sharing this information immediately with researchers around the world. Together, participants and researchers are increasing understanding to help lay a path forward for a better future.
You may be able to help if you are 55 to 90 years of age and ...
- Are in good health
- Have little to no memory concerns or have a diagnosis of early Alzheimer's disease or Mild Cognitive Impairment (MCI)
- Are willing and able to undergo in-clinic assessments, memory testing and other test procedures
- Have a study partner who can accompany you to all clinic visits
This is a free study, and no medication will be involved.
A clinical research study is a carefully designed scientific evaluation conducted by doctors. By taking part in this clinical study, you are helping researchers define the progression of Alzheimer's disease. The ADNI3 research data collected can help in the discovery of potential new treatments that could change the future of how we treat Alzheimer's disease. Today's treatments and cures for debilitating and life-threatening illnesses exist mainly because of people who have volunteered to participate in past clinical studies.
The ADNI3 will have over 60 sites in the U.S. and Canada – find a site near you. You can also call 1-888-223-6495 for more information and help finding a study site near you.